SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2025

SEGMENT INFORMATION

Schedule of Segment Information

b. Segment information:

	Three Months Ended March 31,
(U.S. dollars in thousands)	2025		2024
Revenues from customers	$	10,113	$	3,748
Less:
Employee salaries and related expenses		5,205		5,144
Sub-contractors expense		2,689		2,155
Interest expense		6		390
Interest income		(419)		(513)
Depreciation		346		322
Other segment expenses*		6,018		983
Loss before taxes on income		(3,732)		(4,733)
Tax benefit		(113)		(138)
Segment net loss	$	(3,619)	$	(4,595)

* Other expenses included in net income includes raw materials, rent and utilities and others.

Schedule of Disaggregation of Revenues

c. The following table summarizes the Company’s disaggregation of revenues:

	Three Months Ended March 31,
(U.S. dollars in thousands)	2025		2024
Gaucher disease:
Pfizer (Ireland)	$	6,979	$	1,127
Fiocruz (Brazil)	$	3,016	$	2,550
Fabry disease:
Chiesi (Italy)	$	-	$	-
Total revenues from selling goods	$	9,995	$	3,677
Revenues from license and R&D services	$	118	$	71